United States Department of Veterans Affairs
Seattle Center of Innovation for Veteran-Centered and Value-Driven Care

Steven Zeliadt, PhD

  Zeliadt        PhD    University of Washington
              Health Services, 2004

MPH   University of Washington
              Public Health, 2000

BA     Grinnell College
              Greek and Latin, 1994








Contact Information

Office: 206-277-4175

Sample of Active Projects

Modeling of Health Care Costs of Veterans with Chronic Diseases

VA HSR&D IIR 07-235

Co-Investigator: S. Zeliadt
Principal Investigator: XH Zhou


Differences in Practice Styles in VA and Medicare: Causes and Implications

VA HSR&D IIR 10-150

Co-Investigator: S. Zeliadt
Principal Investigator: P. Hebert


A Joint Evaluation of Surgery-Related Outcomes and Costs Across VAMCs

VA HSR&D IIR 10-365

Co-Investigator: S. Zeliadt
Principal Investigator: XH Zhou


Supporting Objective and Informed Prostate Cancer Treatment Decision Making

WA State Department of Health

Principal Investigator: S. Zeliadt


Prevention Research Centers Cancer Prevention and Control Research Network

Centers for Disease Control and Prevention

Co-Investigator: S. Zeliadt
Principal Investigator: V. Taylor


Adverse Events Associated with Testosterone Treatment in Hypogonaldal Men

National Institute of Aging

Co-Investigator: S. Zeliadt
Principal Investigators: M. Shore, T. Walsh


Long-term Follow-up of the Family and Cancer Therapy Selection (FACTS) Study Participants

Co-Investigator: S. Zeliadt
Principal Investigator: J. Harris

Sample of Selected Publications

Hayanga A, Zeliadt SB, Backhus LM. Lung cancer mortality and residential segregation in the United States. JAMA Surgery. 2013. 148(1):37-42.

Zeliadt SB, Buist DSM, Reid RJ, Grossman DC, Ma J, Etzioni R. Biopsy follow-up of Prostate Specific Antigen tests. Am J Prev Med. 2012. 42(1):37-43; 2012.

Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012. 120(8):1545-51.

Zeliadt SB, Sekaran NK, Hu EY, Slatore CC, Au DH, Backhus L, Wu DY, Crawford J, Lyman GH, Dale DC. Comparison of demographic characteristics, surgical resection patterns and survival outcomes for Veterans and Non-Veterans with non small cell lung cancer in the Pacific Northwest. J Thorac Oncol. 2011: 6(10):1726-1732.

Zeliadt SB, Ramsey SD. Cost-effectiveness of prostate cancer chemoprevention among high-risk men. Expert Rev Pharmacoecon Outcomes Res. 2010: (5):505-8.

Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW. What happens after an elevated PSA test: the experience of 13,591 veterans. J Gen Intern Med. 2010: (11):1205-10.

Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care. 2010: 16(5):e121-30.

Zeliadt SB, Penson DF. Pharmacoecomics of available treatment options for metastatic prostate cancer. Pharmacoeconomics. 2007. 25(4):309-27.

Zeliadt SB, Etzioni RD, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Medical Care. 2007: 45(2): 154-9.

Zeliadt SB, Potosky AL, Penson DF, Etzioni RD. Survival benefit associated with adjuvant androgen deprivation therapy (ADT) combined with radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006. 66(2): 395-402.

Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW.  Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer. 2006. 106(9):1865-74.


 Search for more publications using PubMed